Novo Nordisk at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Novo Nordisk brings 4 presentations to PEGS Europe 2026 in Lisbon. Its program centres on AI and automation in protein and peptide discovery, including cell-free expression used to generate training data for models. It also covers long-acting urocortin-2 analogues for obesity and diabetes.

Organization	PEGS Europe 2026 Attendance
Novo Nordisk Bagsværd, Denmark
novonordisk.com Large pharma Danish pharmaceutical company known for diabetes and obesity medicines, with in-house protein and peptide drug discovery.	Talk Tue Nov 17 9:00am–9:30am IVTT-Accelerated Protein Discovery: Generating Fit-for-Purpose AI Training Data Leveraging Data Science for Enhanced Protein Expression Talk Wed Nov 18 6:30pm–7:00pm High-Throughput Automation Platform for Miniaturised Biophysical Assays: Accelerating Compound Screening with One Click Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 8:50am–9:10am Long Acting, Stable Urocortin-2 Analogues for the Treatment of Obesity and Diabetes Novel Peptide Drug Discovery Talk Thu Nov 19 2:05pm–2:35pm Real-World Progress, Challenges, and Opportunities for AI in Protein and Peptide Discovery Novel Peptide Drug Discovery

Organization

PEGS Europe 2026 Attendance

Novo Nordisk

Bagsværd, Denmark

novonordisk.com

Large pharma

Danish pharmaceutical company known for diabetes and obesity medicines, with in-house protein and peptide drug discovery.

Talk

Tue Nov 17
9:00am–9:30am

IVTT-Accelerated Protein Discovery: Generating Fit-for-Purpose AI Training Data

Leveraging Data Science for Enhanced Protein Expression

Talk